Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The results of a placebo-controlled trial of remdesivir in COVID-19 patients have been published in the Lancet.

In early February scientists in China, supported by the ISARIC Support Centre at the University of Oxford, launched a placebo-controlled randomised trial of remdesivir in patients hospitalised with COVID-19.

The results, published today in the Lancet, found no significant clinical benefit from use of the drug. However, while not statistically significant, the time to clinical improvement and duration of invasive mechanical ventilation were shorter in people treated with remdesivir within 10 days after illness onset, compared to standard care.

One hundred and fifty-eight patients were randomised to remdesivr and 79 patients were randomised to placebo for 14 days. The trial had to be stopped early due to lack of patients, which meant the trial was underpowered and the results are inconclusive.

Professor Peter Horby, a co-investigator on the trial, said: 'It is an outstanding achievement of Dr Cao Bin and his team to have completed a gold-standard clinical trial in the very early days of a major emergency. It is disappointing that we did not see a clear benefit from remdesivir. However, there were suggestions of a possible benefit, particularly in those treated earlier. Ongoing, bigger trials will confirm or refute these findings.'

Read the full story on the University of Oxford website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.